TCIM
STML

TIAA CREF Investment Management’s Stemline Therapeutics, Inc. STML Stock Holding History

TIAA CREF Investment Management’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$786K Sell
61,139
-34,977
-36% -$395K ﹤0.01% 2422
2018
Q4 		$913K Buy
96,116
+45,387
+89% +$589K ﹤0.01% 2321
2018
Q3 		$842K Sell
50,729
-1,670
-3% -$26.8K ﹤0.01% 2508
2018
Q2 		$841K Sell
52,399
-36,280
-41% -$648K ﹤0.01% 2560
2018
Q1 		$1.36M Buy
88,679
+38,237
+76% +$596K ﹤0.01% 2291
2017
Q4 		$787K Sell
50,442
-3,458
-6% -$46.2K ﹤0.01% 2579
2017
Q3 		$598K Sell
53,900
-3,162
-6% -$29.7K ﹤0.01% 2751
2017
Q2 		$525K Sell
57,062
-5,137
-8% -$42.8K ﹤0.01% 2846
2017
Q1 		$532K Buy
62,199
+7,888
+15% +$71.9K ﹤0.01% 2772
2016
Q4 		$581K Sell
54,311
-10,457
-16% -$126K ﹤0.01% 2789
2016
Q3 		$701 Buy
64,768
+318
+0.5% +$2.59K ﹤0.01% 2714
2016
Q2 		$436K Buy
64,450
+11,807
+22% +$74.5K ﹤0.01% 2924
2016
Q1 		$245K Sell
52,643
-7,986
-13% -$39K ﹤0.01% 2953
2015
Q4 		$383K Sell
60,629
-14,440
-19% -$117K ﹤0.01% 2966
2015
Q3 		$663K Hold
75,069
– – ﹤0.01% 2796
2015
Q2 		$884K Buy
75,069
+16,561
+28% +$230K ﹤0.01% 2754
2015
Q1 		$847K Buy
58,508
+14,393
+33% +$220K ﹤0.01% 2709
2014
Q4 		$753K Buy
44,115
+17
+0% +$245 ﹤0.01% 2811
2014
Q3 		$549K Sell
44,098
-2,983
-6% -$36.7K ﹤0.01% 2936
2014
Q2 		$691K Buy
47,081
+5,872
+14% +$90K ﹤0.01% 2917
2014
Q1 		$839K Sell
41,209
-1,330
-3% -$32.3K ﹤0.01% 2739
2013
Q4 		$834K Buy
42,539
+5,300
+14% +$141K ﹤0.01% 2780
2013
Q3 		$1.69M Sell
37,239
-10,564
-22% -$345K ﹤0.01% 2321
2013
Q2 		$1.14M Buy
+47,803
New +$761K ﹤0.01% 2506

Other funds holding STML

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

TIAA CREF Investment Management's STML Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Stemline Therapeutics, Inc. (STML) stake by 36% in Q1 2019, selling an estimated $395K and leaving 61,139 shares worth $786K. The position accounts for ﹤0.01% of the portfolio, ranked #2422.

TIAA CREF Investment Management first reported a position in STML in Q2 2013 and has held it in 24 quarters since. The position peaked at $1.69M in Q3 2013. 98 funds tracked by Wall St. Rank hold STML as of Q1 2019.

  • TIAA CREF Investment Management held 61,139 shares of Stemline Therapeutics, Inc. worth $786K as of Q1 2019.
  • TIAA CREF Investment Management sold 34,977 Stemline Therapeutics, Inc. shares in Q1 2019, an estimated $395K.
  • Stemline Therapeutics, Inc. made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2422 holding.
  • TIAA CREF Investment Management first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Stemline Therapeutics, Inc. position peaked at $1.69M in Q3 2013.
  • 98 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.